1
00:00:03,200 --> 00:00:06,560
Speaker 1: Global business news twenty four hours a day. It's Bloomberg

2
00:00:06,640 --> 00:00:09,760
Speaker 1: dot Com the radio plus mobile lap and on your radio.

3
00:00:10,000 --> 00:00:14,160
Speaker 1: This is a Bloomberg business flag from Bloomberg World Handquarters.

4
00:00:14,200 --> 00:00:17,120
Speaker 1: I'm Charlie Palette. Stocks are higher for a third day.

5
00:00:17,239 --> 00:00:20,400
Speaker 1: Down Jones Industrial Average now up one hundred forty points,

6
00:00:20,400 --> 00:00:23,720
Speaker 1: advancing eight tens of one percent to eighteen thousand, three

7
00:00:23,800 --> 00:00:26,600
Speaker 1: hundred sixty seven. The s MP five hundred index up

8
00:00:26,800 --> 00:00:29,720
Speaker 1: seventeen to twenty one fifty four, a gain of eight

9
00:00:29,720 --> 00:00:32,720
Speaker 1: tenths of one percent, and Stack up thirty eight, also

10
00:00:32,760 --> 00:00:35,800
Speaker 1: a gain of eight tenths of one percent. Tenure down

11
00:00:35,800 --> 00:00:39,040
Speaker 1: twenty seven thirty seconds yield there one point five two percent,

12
00:00:39,360 --> 00:00:42,440
Speaker 1: Gold down twenty three twenty ounce the thirteen thirty three

13
00:00:42,440 --> 00:00:45,520
Speaker 1: a drop of one point seven percent. West Texas Interview

14
00:00:45,600 --> 00:00:48,280
Speaker 1: a crude up four point eight percent. I'm Charlie Pett.

15
00:00:48,360 --> 00:00:52,560
Speaker 1: That's a Bloomberg business flash. You're listening to taking stock

16
00:00:52,640 --> 00:00:56,280
Speaker 1: with Kathleen Hay and Pim Box on Bloomberg Radio. And

17
00:00:56,520 --> 00:00:59,840
Speaker 1: estimated sixteen million adults in the United States are direct

18
00:01:00,000 --> 00:01:04,399
Speaker 1: most each year with dry eye disease and Shire the

19
00:01:04,400 --> 00:01:07,880
Speaker 1: pharmaceutical company shares rose to its highest level in ten

20
00:01:07,959 --> 00:01:10,680
Speaker 1: months in London trading. This after the US Food and

21
00:01:10,720 --> 00:01:15,800
Speaker 1: Drug Administration approved its Zidra drops to treat dry eye disease.

22
00:01:15,840 --> 00:01:18,119
Speaker 1: It's the first treatment for the ailment to be approved

23
00:01:18,360 --> 00:01:20,720
Speaker 1: in more than a decade. Here to tell us more

24
00:01:20,760 --> 00:01:24,120
Speaker 1: is the chief executive of Shire, Dr Fleming Orne Scoff.

25
00:01:24,440 --> 00:01:26,679
Speaker 1: Dr orn Scott, thanks very much for being with us.

26
00:01:26,800 --> 00:01:30,120
Speaker 1: Tell us about this new treatment. How long did it

27
00:01:30,160 --> 00:01:34,160
Speaker 1: take to develop and what's the market? Well, first of all,

28
00:01:34,200 --> 00:01:37,080
Speaker 1: thank you so much for having me on your show today. Well,

29
00:01:37,080 --> 00:01:41,080
Speaker 1: this is a triple first. UM. It's the first product

30
00:01:41,200 --> 00:01:44,480
Speaker 1: that has been approved for both the signs and the

31
00:01:44,560 --> 00:01:48,560
Speaker 1: symptoms of dry eye disease in adults, and as you mentioned,

32
00:01:48,920 --> 00:01:51,120
Speaker 1: there is a loan in the U S sixteen million

33
00:01:51,320 --> 00:01:57,600
Speaker 1: estimated software. UM. It's also a first new product for

34
00:01:57,840 --> 00:02:00,800
Speaker 1: dry eye disease to prove within the last decades by

35
00:02:00,880 --> 00:02:05,920
Speaker 1: the FDA, and it's the first of Talmic product in

36
00:02:06,200 --> 00:02:10,959
Speaker 1: Shire's portfolio to be approved. So it's a triple first today. UM.

37
00:02:11,000 --> 00:02:15,000
Speaker 1: It has taken several years. We acquired the product through

38
00:02:15,040 --> 00:02:19,080
Speaker 1: an acquisition of a company called STA Codes in two

39
00:02:19,120 --> 00:02:24,360
Speaker 1: thousand and thirteen and now two thousand five D patients

40
00:02:24,720 --> 00:02:29,920
Speaker 1: later UM several Phase two particularly one large Phase two study,

41
00:02:30,480 --> 00:02:34,040
Speaker 1: three Phase three studies, and a long term Phase three

42
00:02:34,080 --> 00:02:37,920
Speaker 1: safety study, we arrived at an approval. So it's a

43
00:02:37,919 --> 00:02:40,200
Speaker 1: big day for us, but I think it's an important

44
00:02:40,280 --> 00:02:44,880
Speaker 1: day for patients because now there's an important other opportunity

45
00:02:45,000 --> 00:02:48,799
Speaker 1: force offfers with dry iteices in the US. What is

46
00:02:48,840 --> 00:02:52,040
Speaker 1: the recommended dosage and how would patients use it? And

47
00:02:52,080 --> 00:02:55,840
Speaker 1: perhaps tell us a little bit about price. UM. So

48
00:02:56,080 --> 00:03:00,880
Speaker 1: it's a the active ingredient insider is called the photographs

49
00:03:00,919 --> 00:03:04,720
Speaker 1: five percent and it's UH an eye drop that you

50
00:03:04,840 --> 00:03:09,680
Speaker 1: take twice daily UM. And it's indicated for these signs

51
00:03:09,720 --> 00:03:13,520
Speaker 1: and the symptoms of dry a disease in adults. And

52
00:03:13,639 --> 00:03:17,440
Speaker 1: what would be the estimated price for treatment? So we

53
00:03:17,480 --> 00:03:22,040
Speaker 1: have not announced the price yet. We will soon be

54
00:03:22,760 --> 00:03:28,639
Speaker 1: announcing the price and engage with payers to discuss reimbursements

55
00:03:28,680 --> 00:03:33,840
Speaker 1: so that we can ensure fast and uninhibited reimbursement for

56
00:03:33,880 --> 00:03:37,080
Speaker 1: as many patients as positible. And I'm confident that well

57
00:03:37,280 --> 00:03:40,240
Speaker 1: we will arrive at that dry eye disease. Is it

58
00:03:40,280 --> 00:03:43,640
Speaker 1: associated with inflammation? I mean, could it lead to actual

59
00:03:43,800 --> 00:03:48,360
Speaker 1: damage to the surface of the eye If not treated properly. Yeah, so,

60
00:03:49,000 --> 00:03:54,680
Speaker 1: um it is a condition that affects a large number

61
00:03:54,800 --> 00:04:00,520
Speaker 1: of patients. Sixteen million estimated adults in the U suffer

62
00:04:00,560 --> 00:04:03,800
Speaker 1: from that. UM so you will have both signs and

63
00:04:03,960 --> 00:04:10,240
Speaker 1: symptoms of the condition, and Shires product site or is

64
00:04:10,720 --> 00:04:14,840
Speaker 1: indicated for both the treatment of the signs and the

65
00:04:14,920 --> 00:04:20,400
Speaker 1: symptoms of dry eye disease. It can of course come

66
00:04:20,560 --> 00:04:26,560
Speaker 1: in varying degrees of severity from mild to very severe

67
00:04:26,960 --> 00:04:30,640
Speaker 1: where you see significant impact on the surface of the eye,

68
00:04:30,720 --> 00:04:36,440
Speaker 1: so called the cornea. So it's a pretty uh irritating

69
00:04:36,440 --> 00:04:41,160
Speaker 1: to devastating condition, depending on um the severity of the condition,

70
00:04:41,360 --> 00:04:45,000
Speaker 1: and it requires, of course that you seek in most

71
00:04:45,000 --> 00:04:49,280
Speaker 1: cases the medical care, whether that's an optometrists and optomologists

72
00:04:49,440 --> 00:04:52,360
Speaker 1: or primary care physician that will then take a look

73
00:04:52,360 --> 00:04:56,240
Speaker 1: at the eye and prescribe medicine where appropriate. We're speaking

74
00:04:56,240 --> 00:04:58,760
Speaker 1: with Dr Fleming Orange Scoff. He is the chief executive

75
00:04:58,880 --> 00:05:02,920
Speaker 1: of Shire p l C. Could this become a blockbuster?

76
00:05:03,160 --> 00:05:06,120
Speaker 1: I understand that based on a variety of estimates that

77
00:05:06,120 --> 00:05:08,960
Speaker 1: we've compiled here at Bloomberg, that you could have sales

78
00:05:08,960 --> 00:05:13,040
Speaker 1: of just over a billion dollars by is that consistent

79
00:05:13,080 --> 00:05:17,760
Speaker 1: with your research. Yes, so I think it's quite clear,

80
00:05:17,880 --> 00:05:22,440
Speaker 1: with sixteen million adults in the US suffering from dry dissees,

81
00:05:22,880 --> 00:05:28,200
Speaker 1: many of them today knots being treated and many looking

82
00:05:28,320 --> 00:05:31,720
Speaker 1: for an alternative treatment options, that there is a significant

83
00:05:32,200 --> 00:05:37,480
Speaker 1: commercial opportunity um. And it is true that most analysts

84
00:05:37,480 --> 00:05:40,360
Speaker 1: and also we think this has the opportunity to become

85
00:05:40,880 --> 00:05:44,000
Speaker 1: a blockbuster, which is of course very important. But I

86
00:05:44,000 --> 00:05:47,240
Speaker 1: think the patient perspective that there is an alternative assipatent

87
00:05:47,839 --> 00:05:51,239
Speaker 1: is for me as a physician, the most important. Many

88
00:05:51,279 --> 00:05:54,000
Speaker 1: of us that have worked in octomic medicine for many

89
00:05:54,080 --> 00:05:57,520
Speaker 1: years had worked on various projects projects to get other

90
00:05:57,560 --> 00:06:01,080
Speaker 1: products approved in this indication, and the fact that it

91
00:06:01,200 --> 00:06:03,400
Speaker 1: is not easy, I think can be seen by the

92
00:06:03,400 --> 00:06:05,520
Speaker 1: fact that this is the first partuct to be approved

93
00:06:05,920 --> 00:06:08,400
Speaker 1: for science and symptoms of dry disees ever in the

94
00:06:08,440 --> 00:06:12,080
Speaker 1: first new product to be approved by the FDA in

95
00:06:12,200 --> 00:06:16,440
Speaker 1: ten years for this indication. So I think it's first

96
00:06:16,480 --> 00:06:19,480
Speaker 1: of all, a good opportunity for patients and a good

97
00:06:19,560 --> 00:06:23,559
Speaker 1: day for patients because now there's another alternative for those

98
00:06:23,600 --> 00:06:27,520
Speaker 1: that are suffering from driet disease. You mentioned alternatives for

99
00:06:27,560 --> 00:06:30,200
Speaker 1: the patients, and one alternative, of course, is a drug

100
00:06:30,240 --> 00:06:33,320
Speaker 1: that is already on the market. This is Allergan's Restasis,

101
00:06:33,839 --> 00:06:37,280
Speaker 1: and I understand that about half of her stasis patients

102
00:06:37,520 --> 00:06:41,000
Speaker 1: stopped taking who those who stopped taking it, about half

103
00:06:41,000 --> 00:06:43,680
Speaker 1: of them stopped taking it because because of its cost.

104
00:06:43,920 --> 00:06:48,480
Speaker 1: Is that a factor in in your drug as well? No,

105
00:06:48,720 --> 00:06:52,839
Speaker 1: I think no medicine UM will treat all patients UM.

106
00:06:53,080 --> 00:06:56,920
Speaker 1: And I think the physician in UM, you know, talking

107
00:06:56,960 --> 00:06:59,359
Speaker 1: to the patient and talking with the patient about the

108
00:06:59,400 --> 00:07:03,560
Speaker 1: condition and severe to UM, should make the appropriate choice

109
00:07:03,800 --> 00:07:07,560
Speaker 1: UM for UM a patient. And I don't think one

110
00:07:07,600 --> 00:07:10,840
Speaker 1: size fits all, but I think it's good to have alternatives,

111
00:07:10,880 --> 00:07:14,840
Speaker 1: and I think UM cider Um will provide such an

112
00:07:14,880 --> 00:07:20,320
Speaker 1: alternative for UM eye care professionals and for patients to consider.

113
00:07:20,560 --> 00:07:24,640
Speaker 1: And I think the data in the NABL speaks for themselves,

114
00:07:24,840 --> 00:07:28,840
Speaker 1: and I'm absolutely sure that this is an attractive opportunity

115
00:07:28,960 --> 00:07:31,280
Speaker 1: for many patients. Thank you very much for joining us.

116
00:07:31,360 --> 00:07:35,040
Speaker 1: Dr Fleming Orange Scott is the chief executive of Shire PLC.

117
00:07:35,760 --> 00:07:39,560
Speaker 1: Shares are higher by more than four percent today. You're

118
00:07:39,600 --> 00:07:46,880
Speaker 1: listening to taking Stock. This is Bloomberg coming up on

119
00:07:47,000 --> 00:07:50,800
Speaker 1: taking Stock is real estate in New York Boston, Washington,

120
00:07:50,920 --> 00:07:53,840
Speaker 1: d C. In San Francisco just too expensive for you.

121
00:07:54,240 --> 00:07:57,840
Speaker 1: We'll go forth and go north to Toronto. We've got details.